112 related articles for article (PubMed ID: 27671477)
1. Formulation and evaluation of injectable in situ forming microparticles for sustained delivery of lornoxicam.
Yehia SA; Abdel-Halim SA; Aziz MY
Drug Dev Ind Pharm; 2017 Feb; 43(2):319-328. PubMed ID: 27671477
[TBL] [Abstract][Full Text] [Related]
2. Polymeric and Non Polymeric Injectable In-situ Forming Implant Systems for Sustained Delivery of Lornoxicam: In vitro and In vivo Evaluation.
Yehia SA; Halim SAA; Aziz MY
Curr Drug Deliv; 2018; 15(8):1193-1203. PubMed ID: 29557743
[TBL] [Abstract][Full Text] [Related]
3. Development of Biodegradable Injectable In situ Forming Implants for Sustained Release of Lornoxicam.
Christian R; Thakkar V; Patel T; Gohel M; Baldaniya L; Shah P; Pandya T; Gandhi T
Curr Drug Deliv; 2019; 16(1):66-78. PubMed ID: 30264681
[TBL] [Abstract][Full Text] [Related]
4. A novel in situ forming drug delivery system for controlled parenteral drug delivery.
Kranz H; Bodmeier R
Int J Pharm; 2007 Mar; 332(1-2):107-14. PubMed ID: 17084049
[TBL] [Abstract][Full Text] [Related]
5. Structure formation and characterization of injectable drug loaded biodegradable devices: in situ implants versus in situ microparticles.
Kranz H; Bodmeier R
Eur J Pharm Sci; 2008 Jul; 34(2-3):164-72. PubMed ID: 18501569
[TBL] [Abstract][Full Text] [Related]
6. Non-ionic Surfactant Based In Situ Forming Vesicles as Controlled Parenteral Delivery Systems.
Ammar HO; Ibrahim M; Mahmoud AA; Shamma RN; El Hoffy NM
AAPS PharmSciTech; 2018 Apr; 19(3):1001-1010. PubMed ID: 29110291
[TBL] [Abstract][Full Text] [Related]
7. Formulation and evaluation of proniosomes containing lornoxicam.
Madan JR; Ghuge NP; Dua K
Drug Deliv Transl Res; 2016 Oct; 6(5):511-8. PubMed ID: 27255375
[TBL] [Abstract][Full Text] [Related]
8. Depot injectable biodegradable nanoparticles loaded with recombinant human bone morphogenetic protein-2: preparation, characterization, and in vivo evaluation.
Hassan AH; Hosny KM; Murshid ZA; Alhadlaq A; Alyamani A; Naguib G
Drug Des Devel Ther; 2015; 9():3599-606. PubMed ID: 26203226
[TBL] [Abstract][Full Text] [Related]
9. Preparation and pharmacokinetics evaluation of oral self-emulsifying system for poorly water-soluble drug Lornoxicam.
Li F; Song S; Guo Y; Zhao Q; Zhang X; Pan W; Yang X
Drug Deliv; 2015; 22(4):487-98. PubMed ID: 24524289
[TBL] [Abstract][Full Text] [Related]
10. Enhanced targeting efficiency of PLGA microspheres loaded with Lornoxicam for intra-articular administration.
Zhang Z; Bi X; Li H; Huang G
Drug Deliv; 2011; 18(7):536-44. PubMed ID: 21812757
[TBL] [Abstract][Full Text] [Related]
11. A QUALITY BY DESIGN APPROACH: FABRICATION, CHARACTERIZATION AND EVALUATION OF OPTIMIZED TRANSDERMAL THERAPEUTIC SYSTEM FOR ANTIRHEUMATIC LORNOXICAM.
Naeem M; Pervaiz F; Nawaz Z; Yousup M; Ali A; Khalid N; Khan JA
Acta Pol Pharm; 2017 Jan; 74(1):249-266. PubMed ID: 29474780
[TBL] [Abstract][Full Text] [Related]
12. Doxycycline hyclate-loaded bleached shellac in situ forming microparticle for intraperiodontal pocket local delivery.
Phaechamud T; Chanyaboonsub N; Setthajindalert O
Eur J Pharm Sci; 2016 Oct; 93():360-70. PubMed ID: 27552903
[TBL] [Abstract][Full Text] [Related]
13. Injectable long acting chitosan/tripolyphosphate microspheres for the intra-articular delivery of lornoxicam: Optimization and in vivo evaluation.
Abd-Allah H; Kamel AO; Sammour OA
Carbohydr Polym; 2016 Sep; 149():263-73. PubMed ID: 27261750
[TBL] [Abstract][Full Text] [Related]
14. In Situ
Haider M; Elsayed I; Ahmed IS; Fares AR
Pharmaceuticals (Basel); 2021 Jan; 14(1):. PubMed ID: 33466880
[TBL] [Abstract][Full Text] [Related]
15. Influence of cellulose derivative and ethylene glycol on optimization of lornoxicam transdermal formulation.
Shahzad Y; Khan Q; Hussain T; Shah SN
Int J Biol Macromol; 2013 Oct; 61():26-32. PubMed ID: 23827761
[TBL] [Abstract][Full Text] [Related]
16. Experimental optimization of Lornoxicam liposomes for sustained topical delivery.
Joseph J; B N VH; D RD
Eur J Pharm Sci; 2018 Jan; 112():38-51. PubMed ID: 29111151
[TBL] [Abstract][Full Text] [Related]
17. Piroxicam bioadhesive ocular inserts: physicochemical characterization and evaluation in prostaglandin-induced inflammation.
Gilhotra RM; Gilhotra N; Mishra DN
Curr Eye Res; 2009 Dec; 34(12):1065-73. PubMed ID: 19958126
[TBL] [Abstract][Full Text] [Related]
18. Innovation of novel sustained release compression-coated tablets for lornoxicam: formulation and in vitro investigations.
Hamza Yel-S; Aburahma MH
Drug Dev Ind Pharm; 2010 Mar; 36(3):337-49. PubMed ID: 19722915
[TBL] [Abstract][Full Text] [Related]
19. Preparation of an oil suspension containing ondansetron hydrochloride as a sustained release parenteral formulation.
Nguyen TT; Duong VA; Maeng HJ; Chi SC
Drug Deliv Transl Res; 2020 Feb; 10(1):282-295. PubMed ID: 31659599
[TBL] [Abstract][Full Text] [Related]
20. Dissolution enhancement and formulation of rapid-release lornoxicam mini-tablets.
Tawfeek HM; Saleem IY; Roberts M
J Pharm Sci; 2014 Aug; 103(8):2470-83. PubMed ID: 24995853
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
